Product Revenue, Net - U.S was Agios Pharmaceuticals’s largest region in fiscal 2025, bringing in $49.17M of $54.03M (91%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Product Revenue, Net - U.S | $26.82M | $36.40M | $49.17M |
| Product Revenue, Net - Rest Of World | — | $103.00K | $4.86M |
| Total | $26.82M | $36.50M | $54.03M |
Agios Pharmaceuticals brought in $54.03M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 48.0% from $36.50M in fiscal 2024. Product Revenue, Net - U.S was the largest at $49.17M (91.0%), ahead of Product Revenue, Net - Rest Of World at $4.86M (9.0%).
Compared with fiscal 2024, Product Revenue, Net - Rest Of World grew 4,616.5% to $4.86M and Product Revenue, Net - U.S grew 35.1% to $49.17M.
Agios Pharmaceuticals began breaking out Product Revenue, Net - Rest Of World in fiscal 2024, when it brought in $103.00K.
July 2014 Modification was Agios Pharmaceuticals’s largest revenue line in fiscal 2015, bringing in $15.81M of $29.85M (53%).
| Type of Arrangement and Non-arrangement Transactions | FY 2015 |
|---|---|
| July 2014 Modification | $15.81M |
| April 2015 Modification (Supplants Undelivered Elements Of July 2014 Modification) | $11.97M |
| Not Included In Modification Due To High Level Of Uncertainty | $2.08M |
| Total | $29.85M |
Agios Pharmaceuticals brought in $29.85M from its three revenue lines in fiscal 2015, the year ended December 31, 2015. July 2014 Modification was the largest at $15.81M (53.0%), ahead of April 2015 Modification (Supplants Undelivered Elements Of July 2014 Modification) at $11.97M (40.1%) and Not Included In Modification Due To High Level Of Uncertainty at $2.08M (7.0%).
Under Topic 605 was Agios Pharmaceuticals’s largest revenue line in fiscal 2018, bringing in $92.28M of $93.95M (98%).
| Accounting Standards Update | FY 2018 |
|---|---|
| Under Topic 605 | $92.28M |
| Cumulative Effect & Effect Of Change | $1.67M |
| Total | $93.95M |
Agios Pharmaceuticals brought in $93.95M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. Under Topic 605 was the largest at $92.28M (98.2%), ahead of Cumulative Effect & Effect Of Change at $1.67M (1.8%).
Agios Pharmaceuticals (AGIO) reports its revenue by geography, by type of arrangement and non-arrangement transactions and by accounting standards update. In fiscal 2025, Product Revenue, Net - U.S was its largest region, bringing in $49.17M (91.0% of the total), followed by Product Revenue, Net - Rest Of World at $4.86M (9.0%).
Product Revenue, Net - U.S was Agios Pharmaceuticals' largest region in fiscal 2025, bringing in $49.17M, or 91.0% of the $54.03M total across its two regions.
July 2014 Modification was Agios Pharmaceuticals' largest revenue line in fiscal 2015, bringing in $15.81M, or 53.0% of the $29.85M total across its three revenue lines.
Product Revenue, Net - Rest Of World grew faster than Product Revenue, Net - U.S in fiscal 2025, up 4,616.5% from $103.00K to $4.86M. Product Revenue, Net - U.S grew 35.1% to $49.17M.
Every figure comes from Agios Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Agios Pharmaceuticals gives it, and years follow its fiscal calendar.
Agios Pharmaceuticals' revenue by geography goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.